Finance

Lists
Q1 2027 earnings • released • EPS beat +26.10% • Revenue beat +6.76%
See results
KMTS:NASDAQ
Kestra Medical Technologies Ltd
$24.82
+1.93%
(+0.47) 1D
Sep 18, 11:35:00 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KMTS...
Open
$24.35
High
$25.08
Low
$24.35
Mkt. cap
1.48B
Avg. vol.
318.45K
Volume
57.80K
52-wk high
$30.00
52-wk low
$17.38
EPS
-$2.67
Shares outstanding
59.56M
No. of employees
443
Open
$24.35
High
$25.08
Low
$24.35
Mkt. cap
1.48B
Avg. vol.
318.45K
Volume
57.80K
52-wk high
$30.00
52-wk low
$17.38
EPS
-$2.67
Shares outstanding
59.56M
No. of employees
443
News stories
From web sources and news partners
About Kestra Medical Technologies Ltd
CEO-
Employees443
Founded2014
HeadquartersKirkland, Washington, United States
SectorMedical device
Websitekestramedical.com
Analyst ratings
Based on 7 analysts giving stock ratings to KMTS in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for KMTS in the last 3 months.
Highest
Current $24.82
$32.00 (+28.93%)
Average
$30.00 (+20.87%)
Lowest
$28.00 (+12.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew O'Brien
Piper Sandler
Buy
Maintained
$30.00
+20.9%
09/15/2026
Marie Thibault
BTIG
Buy
Reiterated
$32.00
+28.9%
09/15/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$30.00
+20.9%
09/15/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$30.00
+20.9%
09/14/2026
Robbie Marcus
J.P. Morgan
Buy
Initiated
$30.00
+20.9%
08/10/2026
Suraj Kalia
Oppenheimer
Hold
Initiated
-
-
07/21/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$28.00
+12.8%
07/15/2026
David Roman
Goldman Sachs
Hold
Reiterated
$17.00
-31.5%
04/09/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$28.00
+12.8%
03/18/2026
Last report
Sep 14, 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
-$0.46 / -$0.62
+26.10%beat
Revenue / Est. (USD)
30.97M / 29.01M
+6.76%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Revenue
19.37M
22.56M
24.55M
28.64M
Cost of goods sold
10.52M
11.14M
11.65M
12.96M
Cost of revenue
10.52M
11.14M
11.65M
12.96M
Research and development expenses
4.00M
4.88M
4.97M
5.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
33.73M
38.30M
42.70M
49.39M
Operating expense
37.73M
43.18M
47.67M
55.03M
Total operating expenses
48.25M
54.32M
59.32M
67.98M
Operating income
-28.88M
-31.76M
-34.76M
-39.34M
Other non operating income
2.83M
-891.00K
359.00K
319.00K
EBT including unusual items
-25.79M
-32.75M
-34.13M
-38.64M
EBT excluding unusual items
-25.79M
-32.75M
-34.13M
-38.64M
Income tax expense
33.00K
34.00K
35.00K
192.00K
Effective tax rate
-0.13%
-0.10%
-0.10%
-0.50%
Other operating expenses
-
-
-
-
Net income
-25.83M
-32.78M
-34.17M
-38.84M
Net profit margin
-133.32%
-145.29%
-139.16%
-135.61%
Earnings per share
-0.36
-0.45
-0.40
-0.49
Interest and investment income
2.17M
1.80M
2.16M
2.23M
Interest expense
-1.91M
-1.90M
-1.89M
-1.84M
Net interest expenses
255.00K
-105.00K
275.00K
382.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.85M
-29.38M
-32.78M
-37.02M
Gain or loss from assets sale
280.00K
280.00K
167.00K
434.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps